EV Biologics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a YECO research report →
Price Chart
About the company
EV Biologics, Inc. is a biotechnology enterprise focused on the commercial advancement of extracellular vesicles (EVs), utilizing them as biological agents for diagnostic and therapeutic applications. The company capitalizes on its proprietary, versatile EV platform to engineer innovative vaccines, treatments, and potential cures.
- CEO
- Daniel S. McKinney
- IPO
- 2015
- Employees
- 284
- HQ
- Cheyenne, WY, US
Get TickerSpark's AI analysis on YECO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.09K
- P/E
- -0.04
- PEG
- 0.00
- P/S
- 0.45
- P/B
- -0.00
- EV/EBITDA
- -15.86
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- -1053.41%
- Net Margin
- -1053.41%
- ROE
- 4.63%
- ROIC
- 16.63%
Latest fiscal year · YoY change
- Revenue
- $178.36K+264.7%
- Gross Profit
- $0-100.0%
- Op Income
- $-298,569
- Net Income
- $-298,570+76.4%
- EPS
- $-0.03+75.7%
- OCF Growth
- +96.1%
- FCF Growth
- +96.2%
- 52W High
- $0.11
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.02
- Beta
- 0.45
- RSI (14)
- 86
- Avg Volume
- 820
No earnings-call transcripts are available for YECO yet.
- Free Float
- 100.0%
- Shares Outstanding
- 10.22M
- Float Shares
- 10.22M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 31, 19 | McKinney Daniel S | other | 25,000,000 |
| Dec 18, 18 | McKinney Daniel S | other | 900 |
| Nov 27, 18 | McKinney Daniel S | other | 200 |
| Nov 17, 18 | McKinney Daniel S | other | 300 |
| Nov 8, 18 | McKinney Daniel S | other | 200 |
| Oct 24, 18 | McKinney Daniel S | other | 300 |
| Oct 17, 18 | McKinney Daniel S | other | 25,000,000 |
| Nov 24, 15 | DU WENGE | buy | 1,733,426 |
| Oct 20, 15 | DU WENGE | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our YECO coverage
Recent articles, reports, and earnings notes.
No research on YECO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate YECO report →United States Lime & Minerals (NASDAQ:USLM) and Yulong Eco-Materials (OTCMKTS:YECO) Critical Contrast
defenseworld.net · Dec 27
Smith-Midland (NASDAQ:SMID) and Yulong Eco-Materials (OTCMKTS:YECO) Critical Review
defenseworld.net · Oct 26
EV Biologics Updates on Funding and Sales
accesswire.com · Oct 2
EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic
accesswire.com · Aug 16
EV Biologics Appoints Senior Investment Banker as Corporate Finance Director
accesswire.com · Aug 7
EV Biologics Hires Senior Chief Financial Officer
accesswire.com · Aug 2
EV Biologics Updates on NFT Minting
accesswire.com · Sep 28
EV Biologics Updates on NFT Warrant Dividend Distribution
accesswire.com · Aug 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.